The SMN2 copy number ranges from 0 to ≥4 copies across the SMA population, where a higher SMN2 copy number is usually associated with a milder phenotype, establishing SMN2 as the best renowned prognostic biomarker so far (Wirth, 2021). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.